American Society of Hematology

Figure 3

DFS according to BCR-ABL transcript reduction during dasatinib treatment. (A) BCR-ABL levels < 10−3 at day 22 (n = 10) versus patients who never achieved levels < 10−3 during dasatinib induction treatment (n = 7). (B) BCR-ABL levels < 10−3 (n = 25) or ≥ 10−3 (n = 23) at day 85.

DFS according to BCR-ABL transcript reduction during dasatinib treatment. (A) BCR-ABL levels < 10⁻³ at day 22 (n = 10) versus patients who never achieved levels < 10⁻³ during dasatinib induction treatment (n = 7). (B) BCR-ABL levels < 10⁻³ (n = 25) or ≥ 10⁻³ (n = 23) at day 85.

This Feature Is Available To Subscribers Only